<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="693">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>11/10/2005</approvaldate>
  <actrnumber>ACTRN12605000625673</actrnumber>
  <trial_identification>
    <studytitle>A Phase I, open label study of extended dosing with PatrinTM in combination with temozolomide in the treatment of patients with advanced melanoma.</studytitle>
    <scientifictitle>A Phase I, open label study of extended dosing with Patrin in combination with temozolomide in the treatment of patients with advanced melanoma. Part 1- to establish a dose for Part 2.  Part 2 to test efficacy and safety of the dose established in Part 1.</scientifictitle>
    <utrn />
    <trialacronym>PAT/105</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patrin combined with temozolomide for 6 cycles.</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part 1 - to select a dose for further study based upon safety (dose limiting toxicties).</outcome>
      <timepoint>At day 28.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part 2 - to safety and efficacy based upon AE reports through out study and tumour measurements at Cycle 2.</outcome>
      <timepoint>Throughout study and at Cycle 2.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the safety profile of the combination of PatrinTM administered orally for up to 14 days per cycle and TMZ administered orally for Day 1-5 of each cycle, repeated every 28 days and, to determine the qualitative and quantitative toxicity and reversibility of toxicity of the combination of PatrinTM with TMZ administered in this fashion.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate the clinical pharmacodynamics of PatrinTM with TMZ when administered in this fashion.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate anti-tumour activity of PatrinTM with TMZ when administered in this fashion.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Unresectable stage 3 /4 measurable (RECIST criteria), histologically proven cutaneous melanoma or unknown primary with melanoma metastases, without systemic treatment for metastatic disease.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>132</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KuDOS Pharmaceuticals Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>ORION Clinical Services (Aust) Pty Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ashford Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Yvonne Egan Davidson</name>
      <address>ORION Clinical Services Australia Pty Ltd
Level 1
141 Osborne Street
South Yarra VIC 3141</address>
      <phone>+61 3 98671064</phone>
      <fax>+61 3 98671086</fax>
      <email>yvonne.egandavidson@orioncro.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Yvonne Egan Davidson</name>
      <address>ORION Clinical Services Australia Pty Ltd
Level 1
141 Osborne Street
South Yarra VIC 3141</address>
      <phone>+61 3 98671064</phone>
      <fax>+61 3 98671086</fax>
      <email>yvonne.egandavidson@orioncro.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>